The PD-1/PD-L1 immune checkpoint blockade allows to potentiate antitumor immunity by inhibiting immunosuppressive signals from co-inhibitory molecules, and this has achieved great success in many malignant tumors [35–39]. The gene discussed is CD274; the disease is cancer.